Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01261247 · ClinicalTrials.gov registry record · Phase 2
Panobinostat in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
A Phase 2 study of Peripheral T-Cell Lymphoma and Anaplastic Large Cell Lymphoma, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 2
- Development phase
- 41
- Enrollment target
- 2
- Study locations
NCT01261247 is a Phase 2 study of Peripheral T-Cell Lymphoma and Anaplastic Large Cell Lymphoma that has completed, run by Mayo Clinic. The registered enrollment target is 41 participants, below the 105-participant average among 34 other Peripheral T-Cell Lymphoma trials with a reported enrollment target (61% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT01261247, a Phase 2 study of Peripheral T-Cell Lymphoma and Anaplastic Large Cell Lymphoma, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 41 participants
- Enrollment target
- 2
- Study locations
Study Summary
Panobinostat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. This phase II trial is studying how well panobinostat works in treating patients with relapsed or refractory non-Hodgkin lymphoma
Conditions Studied
Interventions
- OTHER laboratory biomarker analysis
- DRUG panobinostat
- OTHER flow cytometry
- GENETIC DNA analysis
- GENETIC western blotting
Study Locations (2)
Arizona
- Mayo Clinic in Arizona - Scottsdale
Minnesota
- Mayo Clinic - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2011-01-17 |
| Est. Completion | 2019-12-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01261247
The ClinicalTrials.gov registry entry for NCT01261247 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 105-participant average among 34 other Peripheral T-Cell Lymphoma trials with a reported enrollment target (61% lower). The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Peripheral T-Cell Lymphoma appearing as the primary indexed condition, and to 5 interventions - of which laboratory biomarker analysis is the first listed.
NCT01261247 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Arizona, Minnesota.
Frequently Asked Questions
What is clinical trial NCT01261247 about?
NCT01261247 is a clinical study titled "Panobinostat in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma". Panobinostat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. This phase II trial is studying how well panobinostat works in treating patients with relapsed or refractory non-Hodgkin lymphoma
What is the current status of trial NCT01261247?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 41 participants. The study started on 2011-01-17. Estimated completion is 2019-12-02.
What conditions does trial NCT01261247 study?
This clinical trial studies the following conditions: Peripheral T-Cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Adult Nasal Type Extranodal NK/T-cell Lymphoma, Hepatosplenic T-cell Lymphoma.
What interventions are being tested in trial NCT01261247?
The interventions under investigation include: laboratory biomarker analysis (OTHER), panobinostat (DRUG), flow cytometry (OTHER), DNA analysis (GENETIC), western blotting (GENETIC).
Who is sponsoring clinical trial NCT01261247?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01261247 being conducted?
This trial has 2 study locations across Arizona, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Peripheral T-Cell Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase II, Single-center, Single-arm Study Evaluating the Safety and Efficacy of Golidocitinib in the Management of Newly Diagnosed Peripheral T Cell Lymphoma Patients (GOLDEN Study) and Correlative Study
RECRUITING · Phase 2
-
Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma
RECRUITING · Phase 2
-
CD30 CAR for Relapsed/Refractory CD30+ T Cell Lymphoma
RECRUITING · Phase 2
-
Amping up With PemJAK
RECRUITING · Phase 2
-
Romidepsin and Lenalidomide in Treating Patients With Previously Untreated Peripheral T-Cell Lymphoma
ACTIVE NOT RECRUITING · Phase 2
-
Letermovir for the Prevention of Cytomegalovirus Reactivation in Patients With Hematological Malignancies Treated With Alemtuzumab
COMPLETED · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.